People in the News: Uwe Staub

Premium

Epigenomics announced that it has appointed its chief operating officer Uwe Staub to serve on the company's executive board. Staub has been with Epigenomics since 2008, and his portfolio has including product development, R&D, medical and regulatory affairs, customer support, and manufacturing. He also previously held posts at Abbott Diagnostics, Digene, and Qiagen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Sciencethis week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.